Senores Pharmaceuticals has announced its unaudited financial results for the quarter ended June 30, 2026, reporting strong financial and operational performance across key business segments.

The company delivered broad-based growth during Q1 FY27, supported by continued momentum in regulated and emerging markets, improved profitability, expansion of its product portfolio, and increasing manufacturing and commercialisation capabilities.

During Q1 FY27, Senores reported total revenue of INR 180.2 crore, registering a 35.9 percent Year over Year (YoY) growth. The Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) increased sharply to INR 54 crore, growing 87 percent YoY, while Profit After Tax (PAT) reached INR 31 crore, reflecting a 56 percent YoY increase. The strong improvement in EBITDA was accompanied by an approximately 800 basis points expansion in margins on a YoY basis, reflecting the company's continued focus on manufacturing and cost efficiency.

Revenue from regulated markets stood at INR 127.8 crore in Q1 FY27, registering a strong 41.9 percent YoY growth. The performance was supported by continuous expansion of the company's product portfolio and differentiated sales and distribution channels.

The company has nearly doubled its regulated markets portfolio over the past year, increasing its approved Abbreviated New Drug Applications (ANDAs) from 30 as of June 2025 to 58 approved ANDAs as of June 2026. Of these, 23 ANDAs have already been commercialised, strengthening the company's product pipeline and providing visibility for future launches.

Revenue from emerging markets stood at INR 37.6 crore in Q1 FY27, reflecting a 29.6 percent YoY growth. EBITDA margins stood at approximately 14 percent, supported by an increasing focus on niche products and streamlined go-to-market strategies. The business has also turned cash flow positive, reflecting continued improvement in operational efficiency and financial performance.

The India-focused branded generics business recorded revenue of INR 8 crore in Q1 FY27, compared with INR 8.2 crore in the corresponding quarter of the previous year.

The company continued to strengthen its manufacturing and commercialisation platform during the quarter, supporting its long-term growth strategy across regulated and emerging markets.

The addition of the Baroda-based US Food and Drug Administration (FDA)-approved manufacturing plant is expected to enhance scalability, deepen access to regulated markets, enable accelerated product launches, improve operating leverage and margins, and expand Contract Development and Manufacturing Organisation (CDMO) and CMO opportunities.

Production has already ramped up at the Apnar facility, with full-scale expansion expected over the next 12-18 months. The facility is expected to further strengthen the company's manufacturing capabilities and support its growth across global markets.

The company's specific-purpose marketing and distribution subsidiaries are also expected to scale up significantly over the coming years, supporting the structural expansion of its US business.

Commenting on the Q1 FY27 performance, Swapnil Shah, Managing Director, Senores Pharmaceuticals, said, “We have delivered a healthy performance in the first quarter of FY27, building on the strong momentum from the previous year and driven by our well-defined strategic priorities, despite a challenging operating environment. Our regulated markets business delivered strong performance in Q1 FY27, registering 42 percent Year-over-Year revenue growth. This was driven by the continuous expansion of our product portfolio and differentiated sales and distribution channels. Through a balanced blend of in-house development and targeted acquisitions, we have strategically strengthened our ANDA portfolio.”

He further said, “The emerging markets business is also progressing steadily. With our continued shift towards niche products, we are now at near mid-teens EBITDA margins, while importantly, the business has turned cash flow positive. The addition of the Baroda-based FDA-approved manufacturing plant enhances our scalability, deepens our access to regulated markets, enables accelerated product launches, improves operating leverage and margins, and expands our CDMO and CMO opportunities. Production is already ramped up at the Apnar facility, with full scale-up and further expansion expected over the next 12-18 months.”